Latest Insider Transactions at Phreesia, Inc. (PHR)
This section provides a real-time view of insider transactions for Phreesia, Inc. (PHR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Phreesia, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Phreesia, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 05
2021
|
Amy Beth Van Duyn SVP, Human Resources |
SELL
Open market or private sale
|
Direct |
5,273
-3.14%
|
$363,837
$69.72 P/Share
|
|
Jul 30
2021
|
Edward L Cahill Director |
BUY
Grant, award, or other acquisition
|
Direct |
128
+0.45%
|
$8,704
$68.35 P/Share
|
|
Jul 30
2021
|
Lainie Goldstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
128
+0.89%
|
$8,704
$68.35 P/Share
|
|
Jul 30
2021
|
Michael Weintraub Director |
SELL
Open market or private sale
|
Direct |
10
-0.01%
|
$700
$70.0 P/Share
|
|
Jul 30
2021
|
Michael Weintraub Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10
+0.01%
|
$20
$2.03 P/Share
|
|
Jul 30
2021
|
Chaim Indig Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
102
-0.01%
|
$7,140
$70.0 P/Share
|
|
Jul 30
2021
|
Chaim Indig Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
102
+0.01%
|
$408
$4.71 P/Share
|
|
Jul 29
2021
|
Michael Weintraub Director |
SELL
Open market or private sale
|
Direct |
1,754
-1.04%
|
$122,780
$70.02 P/Share
|
|
Jul 29
2021
|
Michael Weintraub Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,754
+1.03%
|
$3,508
$2.03 P/Share
|
|
Jul 29
2021
|
Chaim Indig Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
6,779
-0.54%
|
$474,530
$70.03 P/Share
|
|
Jul 29
2021
|
Chaim Indig Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,779
+0.27%
|
$20,337
$3.37 P/Share
|
|
Jul 21
2021
|
Michael Weintraub Director |
SELL
Open market or private sale
|
Direct |
2,500
-1.47%
|
$162,500
$65.15 P/Share
|
|
Jul 21
2021
|
Michael Weintraub Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+1.45%
|
$5,000
$2.03 P/Share
|
|
Jul 20
2021
|
Michael Weintraub Director |
SELL
Open market or private sale
|
Direct |
7,500
-4.3%
|
$487,500
$65.08 P/Share
|
|
Jul 20
2021
|
Michael Weintraub Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+4.12%
|
$15,000
$2.03 P/Share
|
|
Jul 16
2021
|
Michael Weintraub Director |
SELL
Open market or private sale
|
Direct |
20,000
-5.48%
|
$1,260,000
$63.89 P/Share
|
|
Jul 16
2021
|
Michael Weintraub Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+9.66%
|
$40,000
$2.03 P/Share
|
|
Jul 08
2021
|
Edward L Cahill Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,605
+8.38%
|
-
|
|
Jul 08
2021
|
Lainie Goldstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,605
+15.63%
|
-
|
|
Jul 08
2021
|
Gillian Munson Director |
SELL
Open market or private sale
|
Direct |
3,055
-6.83%
|
$192,465
$63.46 P/Share
|
|
Jul 08
2021
|
Gillian Munson Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,605
+10.18%
|
-
|
|
Jul 08
2021
|
Cheryl Pegus |
BUY
Grant, award, or other acquisition
|
Direct |
2,605
+14.13%
|
-
|
|
Jul 08
2021
|
Michael Weintraub Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,605
+1.54%
|
-
|
|
Jul 08
2021
|
Mark Douglas Smith Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,605
+23.01%
|
-
|
|
Jun 28
2021
|
Evan Roberts Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
32,075
-5.48%
|
$1,924,500
$60.38 P/Share
|
|
Jun 25
2021
|
Evan Roberts Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,834
-0.31%
|
$110,040
$60.09 P/Share
|
|
Jun 24
2021
|
Evan Roberts Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
21,091
-3.47%
|
$1,265,460
$60.05 P/Share
|
|
Jun 24
2021
|
Edward L Cahill Director |
SELL
Open market or private sale
|
Direct |
5,000
-16.19%
|
$300,000
$60.03 P/Share
|
|
Jun 15
2021
|
Evan Roberts Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
20,000
-1.6%
|
$1,120,000
$56.28 P/Share
|
|
Jun 14
2021
|
Edward L Cahill Director |
SELL
Open market or private sale
|
Direct |
15,000
-17.23%
|
$855,000
$57.65 P/Share
|
|
May 24
2021
|
Cheryl Pegus |
SELL
Payment of exercise price or tax liability
|
Direct |
3,555
-21.19%
|
$159,975
$45.45 P/Share
|
|
May 12
2021
|
Gillian Munson Director |
SELL
Open market or private sale
|
Direct |
1,777
-4.03%
|
$78,188
$44.75 P/Share
|
|
May 04
2021
|
Evan Roberts Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+3.83%
|
$0
$0.84 P/Share
|
|
May 04
2021
|
Chaim Indig Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
123,750
+9.02%
|
$0
$0.84 P/Share
|
|
May 04
2021
|
David Linetsky SVP, Life Sciences |
BUY
Exercise of conversion of derivative security
|
Direct |
45,510
+15.08%
|
$45,510
$1.44 P/Share
|
|
Apr 30
2021
|
Amy Beth Van Duyn SVP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
5,688
+8.97%
|
$45,504
$8.03 P/Share
|
|
Apr 30
2021
|
Edward L Cahill Director |
BUY
Grant, award, or other acquisition
|
Direct |
169
+0.37%
|
-
|
|
Apr 30
2021
|
Lainie Goldstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
169
+1.45%
|
-
|
|
Apr 09
2021
|
Michael J. Davidoff SVP, Payer Business |
SELL
Open market or private sale
|
Direct |
2,134
-1.36%
|
$106,700
$50.96 P/Share
|
|
Apr 09
2021
|
Michael J. Davidoff SVP, Payer Business |
BUY
Exercise of conversion of derivative security
|
Direct |
2,134
+2.64%
|
$8,536
$4.71 P/Share
|
|
Apr 01
2021
|
Edward L Cahill Director |
SELL
Open market or private sale
|
Direct |
15,000
-13.22%
|
$810,000
$54.99 P/Share
|
|
Mar 16
2021
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Direct |
1,578
-0.56%
|
$94,680
$60.15 P/Share
|
|
Mar 15
2021
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Direct |
48,482
-17.97%
|
$2,957,402
$61.38 P/Share
|
|
Feb 19
2021
|
Thomas Altier Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
904
-0.55%
|
$65,992
$73.03 P/Share
|
|
Feb 18
2021
|
Thomas Altier Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
76,272
-18.32%
|
$5,491,584
$72.55 P/Share
|
|
Feb 18
2021
|
Edward L Cahill Director |
SELL
Open market or private sale
|
Direct |
10,000
-4.84%
|
$720,000
$72.63 P/Share
|
|
Jan 29
2021
|
Amy Beth Van Duyn SVP, Human Resources |
SELL
Open market or private sale
|
Direct |
21,829
-8.08%
|
$1,440,714
$66.28 P/Share
|
|
Jan 29
2021
|
Amy Beth Van Duyn SVP, Human Resources |
BUY
Exercise of conversion of derivative security
|
Direct |
18,204
+10.06%
|
$0
$0.84 P/Share
|
|
Jan 22
2021
|
Thomas Altier Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,495
-0.47%
|
$103,155
$69.7 P/Share
|
|
Jan 20
2021
|
David Linetsky SVP, Life Sciences |
SELL
Open market or private sale
|
Direct |
6,826
-2.29%
|
$443,690
$65.5 P/Share
|